Jessica Walters

Discover an objective suicide risk assessment for patients denying ideation, using Suicide Crisis Syndrome and staged warning signs to guide earlier intervention.

Blood exosomal microRNA markers reveal oxidative-stress subtypes, predict psychosis conversion, and guide early, targeted treatments like MitoQ.

FDA issues CRL for CTx-1301 in ADHD.

Review the highlights from last week's meeting of the American Society for Clinical Psychopharmacology.

Phase 3 at-home data show sublingual dexmedetomidine cuts severe agitation in bipolar disorder and schizophrenia, supporting FDA label expansion.

Real-world claims show opioids remain common in fibromyalgia despite guidance, highlighting safety concerns and interest in FDA-approved non-opioid option Tonmya.

Learn how to spot bipolar mixed features, avoid antidepressant pitfalls, and choose evidence-based antipsychotics.

GLP-1 drugs like semaglutide may curb alcohol and opioid cravings, as trials expand, combos emerge, and interaction risks surface.

Discover APA sessions on OCD therapies, gut-brain microbiome insights, AI, sports psychiatry, and geriatric updates from top clinicians.

Expert shares the use of liquid formulation ADHD medication and how to discuss with patients.

Lisdexamfetamine liquid targets ADHD and binge eating, easing pill-swallowing and sensory barriers to improve adherence.

Federal fast-tracks boost psychedelic research.

Review news from the last week in psychiatry.

Explore how neuromelanin-sensitive MRI noninvasively tracks long-term dopamine and noradrenaline system changes.

Low soluble α2δ‑1 disrupts brain excitation‑inhibition balance in schizophrenia.

Round on the latest news in psychiatry from the last week.

New data shows stable symptoms when switching from atypical antipsychotics to Cobenfy using cross-titration.

AI video screening spots early tardive dyskinesia signs, prompting clinical follow-up and treatment.

Study links schizophrenia’s earlier onset to higher genomic deletion CNV burden, showing future potential for personalized care.

Round on the latest news in psychiatry from the last week.

Emerging student researchers share their award-winning neuroscience and psychiatry projects.

Data suggest PBFT02 therapy boosts progranulin and slows neurodegeneration markers in early FTD.

Faster aging may be linked to schizophrenia, according to new research.

Shared pathophysiology between Alzheimer disease and autism may expand diagnosis and treatment opportunities.

A pharma expert and clinician shares perspectives on developing treatments.

BPL-003 phase 2a part 2 results show reductions in depression symptoms.

Experts share how roluperidone provides a new opportunity in the schizophrenia treatment landscape.

New analysis links traumatic brain injury to later psychosis, prompting long-term screening and follow-up.

A novel form of agomelatine shows positive initial results.

Further data shared on LB-102 for schizophrenia.